Teresa Foy

Teri Foy is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation. At Bristol Myers Squibb, Teri leads the Immuno-Oncologyand Cell Therapy Thematic Research Center. With a mission to drive leadership in the use of immune effector cell-based therapies in hematological and solid cancers, Teri and her team focus on the development and translation of BMS’ early I-O and cell therapy pipeline from discovery through human proof of concept. As part of her research, Teri also oversees close collaborations with other key research areas across the company, as well as external scientific partnerships.

Prior to her role at Bristol Myers Squibb, Teri worked at Celgene for more than five years. She was instrumental in establishing Celgene’s Seattle site, focusing initially on building the I-O strategy and pipeline, and subsequently expanding focus to include oversight of Celgene’s cell therapy research and early development strategy and pipeline. She and her team spearheaded foundational research in numerous novel targets, including innate immune cells, myeloid cells and regulatory T cells.

Earlier in her career, Teri held Seattle-based scientific leadership positions at Corixa Corp. and Glaxo Smith Kline. She also served as the chief scientific officer at VLST, a private company focused on developing therapeutics for autoimmune and inflammatory diseases.

Teri earned her doctorate in immunology from the University of Iowa, a master’s degree in microbiology, and completed her post-doctoral fellowship in immunology at Dartmouth Medical School. Teri has an extensive publication record and holds nearly a dozen patents for novel immune compositions.